First phase I clinical trial of an HIV-1 subtype D gp140 envelope protein vaccine: immune activity induced in all study participants

AIDS. 2008 Jan 2;22(1):149-51. doi: 10.1097/QAD.0b013e3282f174ed.

Abstract

To combat HIV-1 diversity, we are developing a multienvelope vaccine (comprising DNA, vaccinia virus and protein vectors). Toward this goal, we conducted a phase I clinical trial of EnvPro, a gp140 protein formulated in alum. The vaccine was well tolerated and elicited an immune response in every trial participant.

Publication types

  • Clinical Trial
  • Clinical Trial, Phase I
  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't

MeSH terms

  • AIDS Vaccines / administration & dosage
  • AIDS Vaccines / adverse effects
  • AIDS Vaccines / immunology*
  • Adult
  • Female
  • HIV Antibodies / blood
  • HIV Infections / blood
  • HIV Infections / immunology*
  • HIV-1 / immunology*
  • Headache / chemically induced
  • Humans
  • Immunization Schedule
  • Immunization*
  • Injections, Intramuscular
  • Male
  • Recombinant Proteins / immunology
  • env Gene Products, Human Immunodeficiency Virus / biosynthesis
  • env Gene Products, Human Immunodeficiency Virus / immunology*

Substances

  • AIDS Vaccines
  • HIV Antibodies
  • Recombinant Proteins
  • env Gene Products, Human Immunodeficiency Virus
  • gp140 envelope protein, Human immunodeficiency virus 1